Ovarian mesenchymal cells(oMCs)constitute a distinct microenvironment that supports folliculogenesis under physiological conditions.Supplementation of exogenous non-ovarian mesenchymal-related cells has been reported ...Ovarian mesenchymal cells(oMCs)constitute a distinct microenvironment that supports folliculogenesis under physiological conditions.Supplementation of exogenous non-ovarian mesenchymal-related cells has been reported to be an efficient approach to improve ovarian functions.However,the development and cellular and molecular characteristics of endogenous oMCs remain largely unexplored.In this study,we surveyed the single-cell transcriptomic landscape to dissect the cellular and molecular changes associated with the aging of oMCs in mice.Our results showed that the oMCs were composed of five ovarian differentiatedMC(odMC)populations and one ovarian mesenchymal progenitor(oMP)cell population.These cells could differentiate into various odMCs via an oMP-derived route to construct the ovarian stroma structures.Comparative analysis revealed that ovarian aging was associated with decreased quantity of oMP cells and reduced quality of odMCs.Based on the findings of bioinformatics analysis,we designed different strategies involving supplementation with young oMCs to examine their effects on female fertility and health.Our functional investigations revealed that oMCs supplementation prior to ovarian senescence was the optimal method to improve female fertility and extend the reproductive lifespan of aged females in the longterm.展开更多
Both, autologous and allogeneic hematopoietic stem cell transplantation (HSCT) can be used to cure or ameliorate a variety of malignant and non-malignant diseases. The rationale behind this strategy is based on the co...Both, autologous and allogeneic hematopoietic stem cell transplantation (HSCT) can be used to cure or ameliorate a variety of malignant and non-malignant diseases. The rationale behind this strategy is based on the concept of immunoablation using high-dose chemotherapy, with subsequent regeneration of naive T-lymphocytes derived from reinfused hematopoietic progenitor cells. In addition, the use of HSCT allows for the administration of high-dose chemotherapy (whether or not combined with immunomodulating agents such as antithymocyte globulin) resulting in a prompt remission in therapy-refractory patients. This review gives an update of the major areas of successful uses of HSCT in non-malignant gastrointestinal disorders. A Medline search has been conducted and all relevant published data were analyzed. HSCT has been proved successful in treating refractory Crohn’s disease (CD). Patients with refractory celiac disease type II and a high risk of developing enteropathy associated T-cell lymphoma have shown promising improvement. Data concerning HSCT and mesenchymal SCT in end-stage chronic liver diseases are encouraging. In refractory autoimmune gastrointestinal diseases high-dose chemotherapy followed by HSCT seems feasible and safe and might result in long-term improvement of disease activity. Mesenchymal SCT for a selected group of CD is promising and may represent a significant therapeutic alternative in treating fistulas in CD.展开更多
目的:构建骨髓间充质干细胞(BMMSC)与多发性骨髓瘤(MM)细胞共培养体系,探讨共培养后BMMSC对M M细胞迁移和归巢的影响。方法:采用贴壁筛选法培养绿色荧光蛋白(GFP)小鼠BM M SC,建立M M细胞株XG-7细胞和BMMSC间接及直接共培养体系;用CD13...目的:构建骨髓间充质干细胞(BMMSC)与多发性骨髓瘤(MM)细胞共培养体系,探讨共培养后BMMSC对M M细胞迁移和归巢的影响。方法:采用贴壁筛选法培养绿色荧光蛋白(GFP)小鼠BM M SC,建立M M细胞株XG-7细胞和BMMSC间接及直接共培养体系;用CD138磁珠法分离直接共培养的XG-7细胞及BMMSC,用台盼蓝染色计数法检测XG-7细胞的增殖水平、Annexin V/PI测定细胞凋亡水平、单丹(磺)酰戊二胺(MDC)法检测细胞自噬泡数量、在共聚焦显微镜下动态观察BMMSC与PE-CD138标记的XG-7细胞共培养过程的分子流向和分布。结果:经共培养后,BMMSC促进XG-7细胞增殖;单独培养后凋亡率为(17.90±1.46)%,直接和间接共培养后凋亡率分别降至(6.23±0.12)%和(6.97±0.03)%(P<0.01);XG-7细胞单独培养及与BMMSC共培养后,荧光显微镜下均可出现自噬,共培养后的XG-7细胞自噬现象相对少见;在共聚焦荧光显微镜下XG-7细胞是以极化的胞膜区同BMMSC接触,加入甲基β环糊精后极化现象消失。结论:BMMSC可促进XG-7细胞的生长,且增强XG-7细胞抗凋亡及抗自噬能力,影响骨髓瘤细胞的迁移和归巢。展开更多
基金supported by the National Key Research and Development Program of China (2022YFC2703800)the National Natural Science Foundation of China (82230051)the 2115 Talent Development Program of China Agricultural University (1021-00109022)。
文摘Ovarian mesenchymal cells(oMCs)constitute a distinct microenvironment that supports folliculogenesis under physiological conditions.Supplementation of exogenous non-ovarian mesenchymal-related cells has been reported to be an efficient approach to improve ovarian functions.However,the development and cellular and molecular characteristics of endogenous oMCs remain largely unexplored.In this study,we surveyed the single-cell transcriptomic landscape to dissect the cellular and molecular changes associated with the aging of oMCs in mice.Our results showed that the oMCs were composed of five ovarian differentiatedMC(odMC)populations and one ovarian mesenchymal progenitor(oMP)cell population.These cells could differentiate into various odMCs via an oMP-derived route to construct the ovarian stroma structures.Comparative analysis revealed that ovarian aging was associated with decreased quantity of oMP cells and reduced quality of odMCs.Based on the findings of bioinformatics analysis,we designed different strategies involving supplementation with young oMCs to examine their effects on female fertility and health.Our functional investigations revealed that oMCs supplementation prior to ovarian senescence was the optimal method to improve female fertility and extend the reproductive lifespan of aged females in the longterm.
文摘Both, autologous and allogeneic hematopoietic stem cell transplantation (HSCT) can be used to cure or ameliorate a variety of malignant and non-malignant diseases. The rationale behind this strategy is based on the concept of immunoablation using high-dose chemotherapy, with subsequent regeneration of naive T-lymphocytes derived from reinfused hematopoietic progenitor cells. In addition, the use of HSCT allows for the administration of high-dose chemotherapy (whether or not combined with immunomodulating agents such as antithymocyte globulin) resulting in a prompt remission in therapy-refractory patients. This review gives an update of the major areas of successful uses of HSCT in non-malignant gastrointestinal disorders. A Medline search has been conducted and all relevant published data were analyzed. HSCT has been proved successful in treating refractory Crohn’s disease (CD). Patients with refractory celiac disease type II and a high risk of developing enteropathy associated T-cell lymphoma have shown promising improvement. Data concerning HSCT and mesenchymal SCT in end-stage chronic liver diseases are encouraging. In refractory autoimmune gastrointestinal diseases high-dose chemotherapy followed by HSCT seems feasible and safe and might result in long-term improvement of disease activity. Mesenchymal SCT for a selected group of CD is promising and may represent a significant therapeutic alternative in treating fistulas in CD.
